Mortality and Morbidity After Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study
- 16 April 2011
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 18 (10), 2988-2996
- https://doi.org/10.1245/s10434-011-1715-2
Abstract
To test whether the rates of in-hospital mortality, complications, and transfusions are higher in patients treated with cytoreductive nephrectomy (CNT) for metastatic renal cell carcinoma (mRCC) relative to patients treated with nephrectomy (NT) for non-mRCC.This publication has 22 references indexed in Scilit:
- Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell CarcinomaJournal of Urology, 2008
- Analysis of Complications Following Partial and Total Nephrectomy for Renal Cancer in a Population Based SampleJournal of Urology, 2007
- Laparoscopic cytoreductive nephrectomy: The M. D. Anderson Cancer Center experienceUrology, 2006
- A contemporary evaluation of cytoreductive nephrectomy with tumor thrombus: Morbidity and long-term survivalUrologic Oncology: Seminars and Original Investigations, 2004
- Cytoreductive Nephrectomy in Patients With Metastatic Renal Cancer: A Combined AnalysisJournal of Urology, 2004
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- Cytoreductive Surgery for Stage IV Renal Cell CarcinomaJournal of Urology, 1995
- Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectivesJournal of Clinical Epidemiology, 1993
- Cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinomaUrology, 1993